ZyVersa Therapeutics highlights data on NLRP3 inflammasome inhibition

ZyVersa Therapeutics (ZVSA) highlights newly published data demonstrating cardioprotective effects and improvements in metabolic parameters with inhibition of NLRP3 inflammasome pathways in an obese animal model of heart failure and type 2 diabetes. The new study data were published in the peer-reviewed journal, Biomedicine & Pharmacotherapy. In the publication titled The NLRP3-inflammasome inhibitor MCC950 improves cardiac function in a HFpEF mouse model, the researchers report data from studies conducted in a mouse model that develops HFpEF and comorbidities including obesity, type 2 diabetes, and hypertension. Inhibition of Inflammasome NLRP3 pathways: Attenuated circulating levels of pro-inflammatory cytokine, IL-18, and lowered macrophage infiltration into the heart leading to a substantial reduction in cardiac inflammation. Reduced cardiac hypertrophy and fibrosis, and improved cardiac diastolic function. Reduced fat mass, adipocyte size, and macrophage infiltration into visceral adipose tissue associated with obesity and metabolic disease. Improved glucose homeostasis and insulin sensitivity.